Key statistics
On Monday, Roche Holding AG (ROP:SWX) closed at 320.70, -14.46% below its 52-week high of 374.90, set on Feb 24, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 322.00 |
|---|---|
| High | 323.50 |
| Low | 317.40 |
| Bid | -- |
| Offer | -- |
| Previous close | 320.70 |
| Average volume | 1.38m |
|---|---|
| Shares outstanding | 809.25m |
| Free float | 731.55m |
| P/E (TTM) | 19.99 |
| Market cap | 260.46bn CHF |
| EPS (TTM) | 16.04 CHF |
Data delayed at least 15 minutes, as of Mar 16 2026 16:39 BST.
More ▼
- Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions
- Assemblée générale annuelle 2026 de Roche
- Roche Annual General Meeting 2026
- Roche Generalversammlung 2026
- [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
- New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
- Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
- [Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
- FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
- Change to the Roche Enlarged Corporate Executive Committee
More ▼
